Exercise program targets metabolic risks in cancer survivors

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * BREAST CANCER COHORT: * Women newly diagnosed (stage I-III) breast cancer * Are overweight or obese with the following criteria (determined by study team at eligibility screening): body mass index (BMI) \> 25 kg/m\^2 (calculated using height and weight; an upper limit BMI will not be set; we will rely on obtaining physicians? clearance to assess full eligibility) or body fat \> 30% (estimated by bioelectrical impedance), and waist circumference \> 35 in * Have undergone a lumpectomy or mastectomy * Have completed cancer-related treatment within the past 3 years * Speak English or Spanish * Are in breast cancer remission with no detectable disease present * Able to initiate a supervised exercise program (free from any cardiovascular, respiratory or musculoskeletal disease or joint problems that preclude moderate physical activity) * Free from history of chronic disease including uncontrolled diabetes (fasting blood glucose \> 125 mg/dL), hypertension (blood pressure \> 130/90 mmHg) or thyroid disease (\< 0.4 or \> 4.0 mIU/L); this will be determined by review of medical records and/or physician clearance * Have not experienced a weight reduction \>= 10% within past 6 months * Currently participate in less than 60 minutes of structured exercise/week * No planned reconstructive surgery with flap repair during trial and follow-up period * May use adjuvant endocrine therapy if use will be continued for duration of study intervention * Do not smoke (no smoking during previous 12 months) * Willing to travel to the exercise facility at University of Southern California (USC) * PROSTATE CANCER COHORT: * Men \> 18 diagnosed with prostate cancer for which antiandrogen therapy (ADT) (castration therapy) is being prescribed for at least 16 weeks; castration may be achieved surgically or using gonadotrophin releasing hormone (LHRH) agonists (i.e. leuprolide, goserelin, etc.) or LHRH antagonists (i.e. degarelix) * Additional ADT agents may be concurrently administered (abiraterone, bicalutamide, enzalutamide, etc.) * Men must be obese (BMI \> 25) and sedentary (\< 60 minutes of structured exercise per week) Exclusion Criteria: * Patients with metastatic disease (BREAST ONLY) * Have not completed surgery, chemotherapy, or radiation treatment associated with their diagnosis; a washout period of a minimum of 6 weeks is required from the last anti-cancer treatment received except hormonal therapy * Patients with a history of any musculoskeletal, cardiorespiratory or neurological diseases that preclude the participation in exercise must be evaluated by their physician to assess if they are suitable to proceed on study * Are planning reconstructive surgery with flap repair during trial and follow-up period * Are unable to travel to the exercise facility at USC